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Genome editing technologies such as Zinc Finger nucleases, TALENS and CRISPR/Cas9 have 
recently emerged as tools with the potential to revolutionise cellular therapy. This is 
particularly exciting for the field of regenerative medicine, where the large-scale, quality 
controlled editing of large numbers of cells could generate essential cellular products ready 
to move towards the clinic. This review details recent progress towards generating HLA Class-
I null platelets using genome editing technologies for beta-2-microglobulin deletion, 
generating a universally transfusable cellular product. In addition, we discuss various 
methods for megakaryocyte (MK) production from human pluripotent stem cells and 
subsequent platelet production from the MKs. As well as simply producing platelets, 
differentiating MK cultures can enable us to understand megakaryopoeisis in vivo and take 
steps towards ameliorating bleeding disorders or deficiencies in MK maturation in patients. 
Thus by intersecting both these areas of research, we can produce optimised differentiation 
systems for the production of universal platelets, thus offering a stable supply of platelets for 
difficult-to-match patients and providing areas with transmissible disease concerns or an 
unpredictable supply of platelets with a steady supply of quality controlled platelet units. 
 
Introduction 
Although genome editing technologies such as Zinc Fingers and TALENS have been around for 
some time, it is the repurposing of the bacterial CRISPR/Cas9 defence system that has recently 
provided an efficient, affordable and adaptable method for rapid and reproducible gene 
editing1,2. This is particularly exciting for the field of regenerative medicine, where large-scale, 
quality controlled editing of large numbers of cells could generate essential cellular products 
ready to move towards the clinic. In addition to being able to knock specific genes out, the 
CRISPR/Cas9 system also enables the insertion of relatively large constructs into cells3,4, 
enabling the production of recombinant proteins from edited cells, or even more ambitiously, 
the production of cells for the targeted release of therapeutic proteins at specific sites in the 
body. 
 
Platelets and transfusions 
Platelets are one of the few cell types which have no nucleus, which makes them one of the 
most ideal cell types for transfusion after gene editing. In addition, platelets retain their 
functionality after irradiation, reducing the likelihood of nucleated stem or progenitor cells 
surviving in the platelet unit. There is also evidence to suggest that mature megakaryocytes 
can produce platelets effectively, even after irradiation5. Platelets could be one of the safest 
first-in-human stem cell-derived products for transfusion and provide us with an avenue to 
safely use gene editing methodology for the advent of new cellular products and medicines. 
 
Platelets are 2-4m anucleate discoid cells in the circulation6,7 and are responsible for 
clotting. The deficiency of platelets is known as thrombocytopenia and it can have diverse 
causes, including inherited and acquired bone marrow deficiency, chemotherapy, 
radiotherapy, trauma, major surgery, severe infection or hypercoagulation8. Patients with 
thrombocytopenia are susceptible to severe bleeding events, and to prevent this they are 
transfused with donor platelets. Platelet units are generally ABO and Rhesus D matched8,9 to 
avoid alloimmunisation against RhD from the few red cells present in the platelet unit or lysis 
from anti-A/anti-B present in the plasma into which platelets are suspended. However, some 
patients develop antibodies against antigens present on the surface of platelet themselves, 
namely HLA Class I and Human Platelet Antigens (or in rare cases against auto- or drug-
induced antigens)10 (Figure 1). Among these, antibodies against HLA Class I are the most 
common10-12. Patients generally produce these antibodies as a response to previous 
transfusions or pregnancies. However, a certain proportion of individuals in the general 
population also have antibodies against other HLA Class-I types. In one study, 17% of donors 
who had not been either pregnant or previously transfused had antibodies against HLA Class 
I13, potentially posing a risk of rejection during standard platelet transfusion 
 
Providing matched platelet units for all thrombocytopoenic patients is difficult because 
platelet units have a very short shelf life of only 5 to 7 days at room temperature. There are 
times of year where matched units are difficult to find, and other times when units 
accumulate, wasting the resources used to collect and store them. The logistical challenge of 
providing HLA Class-I matched units for alloimmunised patients leads to significant costs, 
estimated to be in the region of five times the usual cost of platelet provision10,14. If platelets 
could be produced in vitro from “HLA Class-I null” seed cells, this would alleviate the need to 
match platelet units and provide a supply of universal platelets for transfusion. 
 
Megakaryocytes 
In vivo, platelets are produced by multinucleated cells which are known as megakaryocytes 
(MKs)15. These cells make up 0.01-0.03% of nucleated bone marrow cells16 and are large cells 
of 5-50m in diameter with a mean diameter of 19.4 +/-3 m6,17. Megakaryocytes 
differentiate from haematopoietic stem cells (HSCs) in the bone marrow18. As they mature, 
the multiple nuclei of the megakaryocyte are produced by endomitosis18. After becoming 
multinucleate, megakaryocytes then begin cytoplasmic maturation18 during which they 
produce a membrane demarcation system, which is an extension of their cell membrane that 
invaginates into the cell. This forms the production centre for platelets19. Proplatelet 
extensions or large fragments of MKs emanate from the membrane demarcation system into 
the bone marrow sinusoids, where the blood flow buds off nascent platelets from the tip of 
each or breaks up larger fragments of MKs20,21 (Figure 2). Each megakaryocyte is estimated to 
produce 100-1000 platelets and the collective production of platelets is estimated at 1-2 x 
1011 each day18,20. Platelets survive for 7-10 days in the circulation, before being removed by 
the spleen18. 
 
Producing megakaryocytes in vitro. 
Megakaryocytes are found in very small numbers in the bone marrow, thus they cannot be 
harvested and transplanted from one person to another. They differentiate from 
haematopoietic stem cells (HSCs), which are also present in small numbers the bone marrow. 
HSCs can be mobilised from peripheral blood or harvested directly from the bone marrow or 
from cord blood. 22,23. HSCs can be transplanted, but they generate the entire blood system 
and we have no way of directing their differentiation solely towards MKs in vivo. Therefore, 
to generate universal platelets, rather than transplanting MKs or their progenitors, we need 
to produce MKs in vitro and use these for the production of platelet units which we can then 
transfuse.  
 
HSCs can be differentiated with a cytokine cocktail to form mature MKs which were capable 
of platelet production24. However, HSCs cannot be expanded in vitro and their MK production 
efficiency falls well below that required for the generation of clinically relevant platelet 
numbers. In addition, HSC isolation requires either invasive bone marrow sampling or the 
treatment of donors with granulocyte colony stimulating factor for several days before 
donation. It would be beneficial to turn towards a cell type which could be easily generated 
and expanded in vitro.  
 
Induced pluripotent stem cell (iPSC) lines represent a possible alternative source of seed cells. 
While overcoming the potential ethical issues associated with human embryonic stem cells 
(hESCs), iPSCs can produce all differentiated cell types and are infinitely expandable in vitro, 
overcoming the need to repeatedly harvest primary cells. They can also be gene edited and 
quality controlled, generating HLA-Class I knockout lines for the generation of universal 
platelets.  
 
There are several systems which have been developed for the production of MKs from 
pluripotent stem cells (Figure 3). First of all, cytokine cocktails [invariably containing 
thrombopoeitin (TPO)] can be applied to pluripotent cells to mirror MKs’ in vivo 
developmental trajectory and shepherd the cells towards megakaryocyte differentiation25-27. 
This is known as “directed differentiation”. Directed differentiation can be aided by feeder 
layers such as OP9 stromal cells 28,29 upon which ESCs produce sac-like structures30. These sac-
like structures contain large amount of progenitors which can differentiate into mature MKs. 
Ouput can be increased by the treatment of differentiating sacs with VEGF30.  
 
Progressing away from feeders and undefined conditions, megakaryocytes were then 
differentiated from hESCs using TPO, SCF and IL11 in defined media conditions31. These MKs 
were produced in large numbers at around 118 per starting iPSC and could also produce 
platelets that contributed to clot formation in a mouse model. A second group also generated 
MKs from hESCs without feeders in defined conditions using an embryoid body based 
protocol32.  Interestingly, these could also fragment to generate platelet-like particles. 
 
Directed differentiated methods alleviate the risk to patients from transduced or transformed 
cell products, as the cells are unmodified25. Directed differentiation approaches can also be 
combined with the use of bioreactors, as the hPSCs can be loaded onto laminin-coated 
microcarrier beads and the cell suspension stirred as they differentiate into MKs. This can 
increase output per starting hPSC5. However, the cytokine dosage required for these 
protocols remains high, increasing the production costs of any potential cellular product. In 
addition, directed differentiation protocols are still often hampered by low production 
efficiency. 
 
Because of this low efficiency, groups aimed to increase the efficiency of MK differentiation 
with viral transgenes. Platelet release from in vitro derived MKs was increased after 
transduction with CMYC33. Thus the idea of directing cell fate with viral transgenes began to 
gain a foothold. Another group generated cells with megakaryocyte erythroid progenitor 
(MEP)-associated surface marker expression after transducing hESCs which GATA2, TAL1 and 
LMO234. Transducing ESCs with ETV2 and GATA2 generated cells which could form 
megakaryocyte-like colonies in colony forming assays34.  
 
The Eto group then extended their ES-Sac protocol to include viral transgenes. After the 
generation of the sac-like structures, haematopoietic progenitor cells were isolated and 
immortalised by viral transduction with CMYC, BMI1 and BCLXL, enabling expansion for up to 
5 months after transformation35. Upon removal of the viral transgenes, the cells matured and 
produced platelets, demonstrating that despite the immortalisation, the MKs produced 
remain functional. However, an important caveat of this approach is the potential for 
tumorigenesis. The authors observe that after prolonged culture, some clones acquired 
karyotypic anomalies which could generate leukaemia in recipient mice. Because the safety 
controls in place for the production of platelets in vitro would probably involve irradiation of 
the cells before transfusion and BMI1 overexpression could rescue cells from apoptosis36, this 
presents a possible safety concern.  
 
Work in our lab has generated a protocol for the generation of expandable MKs cultures 
without the need for transformation37. This is achieved by the transduction of hiPSCS with 
GATA1, TAL1 and FLI1. Within 20 days in only two cytokine combinations, these cells generate 
a pure population of mature megakaryocytes which can produce platelets in vitro6. These 
cultures can be maintained for up to 120 days in culture without losing their platelet 
production abilities and can be frozen and rethawed.  
 
Bioreactors for the generation of platelets from in vitro produced megakaryocytes. 
 
After the generation of mature megakaryocytes from human pluripotent stem cells, the 
megakaryocytes need to be fragmented to form platelets. In vivo, this is done as or after the 
megakaryocyte approaches the lumen of the bone marrow sinusoids and buds through into 
the circulation. Various models have been proposed through which megakaryocytes form 
platelets18,20,21, however consensus in the field would suggest that blood flow through the 
bone marrow drives the disruption of the megakaryocyte and the formation of 
platelets18,21,38. To achieve this in vitro, bioreactors have been designed to mimic the shear 
the blood flow would exert on megakaryocytes in vivo. These vary significantly in design. A 
recent publication by the Eto group describes a large stirred bioreactor which uses the vertical 
movements of large paddles to fragment mature megakaryocytes39. Microfluidic devices have 
also been designed which adhere megakaryocytes to a fenestrated membrane using fluid 
flow40. Their membranes are then forced through the fenestrated membrane and budded off, 
forming platelets. A third method of deriving platelets from their parent MK involves loading 
a sponge of defined pore sizes with the mature megakaryocytes6,41. Fluid can then be pumped 
through the sponge to encourage the megakaryocytes to release platelets, which due to their 
smaller size can flow freely out of the sponge. Finally, a fourth model has been designed which 
loads the megakaryocytes onto a silk sponge fitted with multiple narrow channels, mimicking 
intramarrow blood vessels. MKs adhere in the multiple channels and bud off their platelets in 
response to media flow42. Almost universally, thus, these bioreactors utilise fluid flow to 
produce platelets. Additionally, the sponge systems are amenable to functionalisation in 
order to mimic the chemical environment of the bone marrow. Most of the systems, apart 
from the first, also separate the parent megakaryocytes from their daughter platelets, 
ensuring the lack of nucleated cells in the final product. In the first system, separation 
between platelets and MKs is done by centrifugation which may adversely affect the platelets’ 
quality as a transfusion product. 
 
HLA Class I deletion 
The HLA system is a series of closely linked genes which together are responsible for the 
presentation of antigens to the immune system and immune surveillance of the body43. HLA 
Class I genes include the classical HLA-A, -B and –C, the non-classical HLA-E, -F and -G and 
MHC Class I chain-related MICA and MICB. Classical HLA Class I proteins are expressed on 
most nucleated cells whereas the non-classical and associated proteins have more restricted 
expression ranges43. HLA Class I presents antigens to CD8++ cytotoxic T lymphocytes. HLA-A, -
C, -E and -G can also present to natural killer (NK) cells,  T cells and CD8+ T cells. Interestingly, 
most anti-platelet antibodies generated by patients who become refractory to transfusion 
are against HLA-A and -B10, thus these represent a possible target for deletion with an aim to 
the transfusion of at-risk patients.  
 
For correct assembly on the cell surface, HLA Class I requires 2 microglobulin. In order to 
delete all HLA Class I without targeting all the genes separately, 2 microglobulin can be 
disrupted. This was first carried out by the lentiviral transduction of iPSCs with shRNA27. This 
resulted in an 87% reduction in the transcript levels of 2 microglobulin without 
compromising the cells’ expression of pluripotency-associated markers. These cells were then 
differentiated into MKs by three sequential cytokine cocktails. Differentiation efficiency was 
not adversely affected by the reduction of HLA Class I. Furthermore, the platelets produced 
from these HLA Class I deficient MKs were functional and survived longer in a mouse model 
for platelet refractoriness than control platelets. This was the first indication that HLA Class I 
deletion is both possible and beneficial for human in vitro-produced platelets. However, with 
this system, HLA Class I levels were reduced but the protein was not completely absent. The 
absence of HLA Class I is reported to cause cytotoxicity by the activation of Natural Killer (NK) 
cells44. Therefore, it was not clear whether the minimal residual levels of HLA Class I were 
sufficient to block this destruction. 
 
HLA Class I knockdown has also been carried out on CD34+ stem cells in order to generate HLA 
Class I knockdown MKs45,46. Again, this was carried out by transduction of the cells with a 
lentivirus encoding anti 2-microglobulin shRNA. These CD34+ cells could then be 
differentiated into megakaryocytes, interestingly at higher efficiency than controls46. They 
also generated higher numbers of platelets. Crucially, HLA Class I knockdown (KD) cells could 
evade antibody dependent cellular cytotoxicity in vitro, indicating that they might escape 
immune surveillance better than control cells45. To investigate the immune response to these 
cells in vivo, the group then generated a mouse model for platelet survival. MKs from KD and 
control CD34+ cells were then injected into NOD/SCID/IL2RC-/- (NSG) mice. Both KD and 
control MKs could produce platelets in vivo, however upon the addition of human anti-HLA 
Class I antibodies, control platelets were destroyed whereas HLA Class I KD platelets survived 
at higher levels for up to 11 days45. This demonstrates the utility of HLA Class I deletion or 
reduction for transfusion, as it could enable the survival of transfused platelets in the 
circulation, despite circulating antibodies against HLA Class I. However, NSG mice will not 
have human NK cells, and this poses a problem for the proper assessment of NK-mediated 
destruction of HLA Class I deleted cells. HLA Class I expression in the CD34+ cells used in these 
studies was 85% of control levels, thus residual protein levels could inhibit the activation of 
NK cells if the cells were exposed to a full human immune system46. However, the levels of 
HLA Class I which are required to appease NK cells remained to be tested.   
 
In order to address this, the authors then turned to a model rat system. They silenced rat HLA 
Class I in fibrosarcoma cells by transducing them with lentivirus encoding shRNA against 2 
microglobulin47. These were then transplanted into rats. Cells which had silenced HLA Class I 
formed larger tumours than control cells, illustrating the idea that HLA Class I removal enables 
cells to evade immune recognition. HLA Class I KD tumours were infiltrated with less CD4+ and 
CD8+ T cells than controls, indicating that the cells elicited poorer lymphocyte activation, 
which they also demonstrated using a T cell proliferation assay. Interestingly, HLA Class I 
silenced tumours did not have increased NK cell infiltration, indicating that the reduction in 
HLA Class I does not activate the ‘missing self’ immune response47,48. In vitro assays also 
suggested that NKs do not recognise fibroblasts expressing more than 10% of the normal 
levels of HLA Class I and as these cells had 15% HLA Class I expression remaining, they could 
escape NK cell recognition.  
 
To mitigate the risk that HLA Class I null cells could be destroyed by NK cells, it could be useful 
to express cell surface receptors which activate inhibitory NK receptors. For example, HLA-E 
binds to NKG2A/CD94 and protects HLA-E-expressing cells from NK-mediated lysis49-51. 
Human HLA-E was expressed in pig cells, which then protected them from lysis in vitro by 
human NK cells, indicating that HLA-E overexpression could be a complementary strategy to 
protect HLA-A, -B and -C null cells from NK-mediated lysis52. HLA-G overexpression has also 
been carried out in hESCs and this also protected ESC-derived epithelial progenitors from NK-
mediated lysis in vitro53. However, HLA-E and -G require 2 microglobulin for assembly of 
their membrane bound forms, therefore using these immune modulators in HLA Class I KO 
cells would require 2 microglobulin re-expression, fused to HLA-E or -G49,54,55.  
 
As gene editing techniques advanced, it became more straightforward to produce 2 
microglobulin KO cells, which could then be used for the differentiation of MKs. This was first 
done in 2014, where the authors used TALE-nucleases to knockout 2 microglobulin by the 
disruption of exon 225. A cytokine-mediated directed differentiation approach to differentiate 
2 microglobulin-/- iPSCs into MKs. The platelets remained HLA Class I null and were activated 
in response to thrombin to a similar extent to controls25. This indicates that HLA Class I null 
platelets can be produced and remain functional. However, it remains to be demonstrated 
whether these HLA Class I null cells are recognised by the human immune system and 
specifically whether they might be targeted for destruction by NK cells. To address this, 
human HLA Class I KO platelets should be assessed in a humanised mouse model which would 
enable the interaction of in vitro-derived platelets with human NK cells in vivo56. This would 
be the first step towards the generation and transfusion of universal platelets.  
 
Quality control of edited cellular products 
The advent of genome engineering also creates a new landscape for the regulation and quality 
control of cellular products. Cells edited with CRISPR/Cas9 need to be assessed for safety 
before approaching clinical trials. Gene editing systems (Summary in Figure 4), as well as the 
clonal selection necessary to start master cell banks of edited iPSCs can introduce potentially 
deleterious mutations into pluripotent stem cells. For example, it has recently been 
demonstrated that human pluripotent stem cell cultures can acquire p53 mutations during 
extended culture57. These mutations may allow cells to outcompete their neighbours, 
eventually taking over the culture58.  
 
In order to address these concerns, strict quality control must be carried out on the starting 
cell population, and repeated at regular intervals during differentiation. Current work in the 
field is addressing which techniques may be best for efficient and sensitive quality control. 
Karyotyping may be useful to identify large abnormalities, whereas qPCR of key loci, 
fluorescence in situ hybridisation and droplet PCR could be useful to identify the emergence 
of smaller mutations59. Combining this with regular analysis of cancer-associated single 
nucleotide polymorphisms by SNP array could enable the early detection of cancer- and 
proliferation-associated mutations60. Pluripotent starting cells should be subjected to a highly 
stringent quality control step, including not only karyotyping but more detailed analyses 
analysing genome integrity such as SNP arrays, FISH or whole genome sequencing analysis. 
The final MK product should also be strictly controlled, possibly including SNP arrays, 
karyotype, clonogenicity assays and the analysis of a panel of markers by flow cytometry.  
 
In addition, there is much concern about potential off-target effects of CRISPR/Cas9, many of 
which can be mitigated by the use of paired Cas9 nickases61 and the use of proteins instead 
of nucleic acids62 but some of which may still be of concern. The starting pluripotent stem cell 
also needs to be available at clinical grade, posing an addition hurdle to line selection for 
differentiation63. Finally, the transplant or transfusion of a human recipient with an edited 
cellular product represents an enormous safety concern for regulators, particularly where the 
cell type or its progenitor or stem cell is long-lived and has the potential to colonise the body 
or generate tumours. Cells should be terminally differentiated and efficiency should be 
regularly analysed, to exclude proliferating progenitors from any potential cellular product. 
Additional layers of security can also be built into the system by the use of suicide genes. For 
example, iPSCs can be transduced with a Caspase 9 which is expressed by treating cells with 
a chemical inducer64.  Tumours from the cells can then be eradicated by treating cells with 
the chemical inducer. Crucially, this is effective in vitro as well as in vivo, providing a rapid 
method to remove any escaping cells, if necessary. 
 
In conclusion, quality control of both the starting pluripotent cell type and the final 
differentiated cell product are critical steps in providing a safe and consistent product. Much 
work remains to be done on determining which quality controls need to be put in place and 
the sooner industry standards are set, the sooner in vitro platelets can progress towards the 
clinic. Many cellular products are already well advanced towards clinical trial65 and defining 
quality control standards remains a critical step in this process. 
 
Perspectives 
Work by multiple groups has demonstrated the robust and reproducible differentiation of 
mature MKs from many cell sources including CD34+ stem cells from peripheral blood, hESCs 
and hiPSCs. MKs have also been transdifferentiated from fibroblasts66. Progress has also been 
made towards the reduction or deletion of 2-microglobulin with a view to generating 
platelets with reduced or absent HLA Class I. However, it still remains to be addressed 
whether in vitro derived HLA Class I KO platelets can survive the human immune system, and 
furthermore whether HLA Class I deletion is the best path towards a universal transfusion 
product67.  Because they degranulate at the site of injury, platelets represent an unrivalled 
method of targeting drugs after haemorrhage or infarction. The systems we use to generate 
them also provide us with a key insight into processes which occur deep in the bone marrow 
during MK maturation. Analysis of differentiating MK cultures can enable us to understand 
megakaryopoiesis in vivo and take steps towards ameliorating bleeding disorders or 
deficiencies in MK maturation in patients. The path towards the clinic is a shorter one for 
platelets than for many other cellular products, however much work still needs to be done 
before we can generate universally transfusable platelets. 
 
Summary points 
• Megakaryocytes can be reproducibly and efficiently differentiated from human 
pluripotent stem cells, enabling us to produce platelets in vitro.  
• The knockdown or deletion of 2 microglobulin can generate HLA Class I knockdown 
or knockout megakaryocytes, which can produce platelets for universal transfusion. 
• Much optimisation is taking place on methods of differentiation, with a particular aim 
to decrease cytokine requirements, increase the generation of mature 
megakaryocytes and reduce culture volume for the production of platelet units. 
• Standard quality control procedures are needed for the production of cellular 
products and the control of gene editing effects need to be factored into all cellular 
therapy production protocols. 
 
Figures 
Figure 1: Immune-recognised platelet antigens. Antigens posing a risk for alloimmunisation 
after platelet transfusions. Common antigens causing the rejection of platelets in Caucasian 
populations are shown in bold. 
 
Figure 2: Megakaryocyte differentiation in vivo. Schematic of megakaryocyte differentiation 
from HSCs in the bone marrow. As they differentiate, MKs move towards the bone marrow 
sinusoids where they adhere to endothelial cells and extend proplatelet extensions or entire 
cell fragments, budding platelets off into the circulation. 
 
Figure 3: Summary of in vitro megakaryocyte differentiation protocols. Schematic of 
optimised protocol for the differentiation of megakaryocytes from pluripotent stem cells, 
either by directed differentiation using cytokines alone, or with the aid of transgenes in 
addition to cytokines. 
 
Figure 4: Methods of gene editing. Gene editing methodologies with possible uses to 
generate universal platelets. Gene targeting is shown in the green panel, which is inefficient 
in most cell types and requires the generation of DNA breaks. Nucleases which can generate 
these targeted breaks are shown in the orange panel. 
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